ADMA Biologics Faces Securities Fraud Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Background: Block & Leviton has announced a securities fraud lawsuit against ADMA Biologics and certain executives, alleging misleading investors from 2024 to 2026, resulting in significant investor losses; the lawsuit claims ADMA falsely reported revenue growth through a channel-stuffing scheme while failing to disclose a related-party distribution relationship with Genesis BioPharma Services.
- Stock Price Volatility: Following the March 24, 2026 report by Culper Research, which revealed that ADMA's growth was driven by excess inventory rather than genuine demand, the company's stock price plummeted from approximately $13.59 to $8.29, indicating market concerns regarding the company's financial health and transparency.
- Investor Eligibility: Investors who purchased ADMA stock between August 9, 2024, and March 25, 2026, and have incurred losses are encouraged to contact Block & Leviton to explore recovery options, suggesting that the lawsuit could impact a broad base of investors who may be eligible for compensation.
- Whistleblower Program: Whistleblowers with non-public information about ADMA are encouraged to assist in the investigation, as they may receive rewards of up to 30% of any successful recovery by providing original information to the SEC, highlighting the potential for increased legal scrutiny and compliance risks for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Faces Securities Fraud Lawsuit
- Lawsuit Background: Block & Leviton has announced a securities fraud lawsuit against ADMA Biologics and certain executives, alleging misleading investors from 2024 to 2026, resulting in significant investor losses; the lawsuit claims ADMA falsely reported revenue growth through a channel-stuffing scheme while failing to disclose a related-party distribution relationship with Genesis BioPharma Services.
- Stock Price Volatility: Following the March 24, 2026 report by Culper Research, which revealed that ADMA's growth was driven by excess inventory rather than genuine demand, the company's stock price plummeted from approximately $13.59 to $8.29, indicating market concerns regarding the company's financial health and transparency.
- Investor Eligibility: Investors who purchased ADMA stock between August 9, 2024, and March 25, 2026, and have incurred losses are encouraged to contact Block & Leviton to explore recovery options, suggesting that the lawsuit could impact a broad base of investors who may be eligible for compensation.
- Whistleblower Program: Whistleblowers with non-public information about ADMA are encouraged to assist in the investigation, as they may receive rewards of up to 30% of any successful recovery by providing original information to the SEC, highlighting the potential for increased legal scrutiny and compliance risks for the company.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, particularly concerning the authenticity of its reported 20% revenue growth in 2025.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced distributors to stockpile ASCENIV to inflate revenue figures, suggesting that without this scheme, the company would have faced a 3% revenue decline instead of the reported 20% growth.
- Stock Price Impact: This news caused ADMA Biologics' stock price to plummet by 29% over two trading days, dropping from $13.59 per share on March 23 to $9.63 per share on March 25, indicating significant market concerns regarding the company's financial health.
- Legal Options: Investors are encouraged to contact BFA for legal support, with the firm offering representation on a contingency fee basis, highlighting its commitment to protecting investor rights.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, encouraging investors to seek further information regarding their legal options.
- Revenue Growth Scrutiny: ADMA reported a 20% revenue growth in 2025, but allegations suggest this was achieved through a channel stuffing scheme to obscure declining demand, with actual revenues potentially declining by 3% had the scheme not been employed.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed ADMA's channel stuffing practices, the company's stock price fell by 29% over two trading days, from $13.59 on March 23 to $9.63 on March 25, indicating significant market concerns over its financial transparency.
- Legal Implications: Investors may have legal recourse, with BFA offering representation on a contingency basis, highlighting a commitment to protecting investor rights while potentially impacting ADMA's future financing capabilities.
See More
Investigation into ADMA Biologics for Securities Violations
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, particularly questioning the authenticity of its reported 20% revenue growth in 2025, suggesting possible channel stuffing to mask declining demand.
- Revenue Growth Concerns: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which artificially inflated revenue; without this scheme, the company would have faced a 3% revenue decline in 2025 instead of the reported growth.
- Stock Price Plunge: The news of the investigation caused ADMA Biologics' stock price to drop by 29% over two trading days, falling from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating severe market concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to submit their information for legal support, with BFA offering representation on a contingency fee basis, highlighting a commitment to protecting investor rights, which may also impact ADMA's future financing capabilities and market trust.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Announcement: Bleichmar Fonti & Auld LLP has launched an investigation into ADMA Biologics for potential violations of federal securities laws, particularly concerning the legitimacy of its reported 20% revenue growth in 2025.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV, artificially inflating revenue; without this scheme, the company would have faced a 3% revenue decline instead of the reported 20% growth.
- Stock Price Plunge: The news of the investigation led to a 29% drop in ADMA's stock price over two trading days, falling from $13.59 per share on March 23 to $9.63 on March 25, indicating significant market concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, highlighting their commitment to protecting shareholder rights.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ADMA Biologics has engaged in securities fraud or other unlawful business practices, prompting investors to reach out for more information, indicating serious concerns regarding corporate governance.
- Short Report Allegations: On March 24, 2026, Culper Research published a short report alleging that ADMA's reported growth is fictitious, driven by channel stuffing and undisclosed related party distributors, estimating a 3% revenue decline in 2025 without channel stuffing, which significantly undermines investor confidence.
- Stock Price Plunge: Following the short report's release, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share on March 24, 2026, reflecting strong market skepticism about the company's financial transparency.
- Withdrawal of Long-term Guidance: On May 6, 2026, ADMA withdrew its long-term financial guidance due to evolving competitive dynamics in the U.S. plasma products and immunoglobulin market, leading to a further stock price drop of $1.61, or 15.97%, to close at $8.47 per share on May 7, indicating increasing market pressures on the company.
See More
ADMA Biologics Faces Securities Fraud Lawsuit
- Lawsuit Background: Block & Leviton has announced a securities fraud lawsuit against ADMA Biologics and certain executives, alleging misleading investors from 2024 to 2026, resulting in significant investor losses; the lawsuit claims ADMA falsely reported revenue growth through a channel-stuffing scheme while failing to disclose a related-party distribution relationship with Genesis BioPharma Services.
- Stock Price Volatility: Following the March 24, 2026 report by Culper Research, which revealed that ADMA's growth was driven by excess inventory rather than genuine demand, the company's stock price plummeted from approximately $13.59 to $8.29, indicating market concerns regarding the company's financial health and transparency.
- Investor Eligibility: Investors who purchased ADMA stock between August 9, 2024, and March 25, 2026, and have incurred losses are encouraged to contact Block & Leviton to explore recovery options, suggesting that the lawsuit could impact a broad base of investors who may be eligible for compensation.
- Whistleblower Program: Whistleblowers with non-public information about ADMA are encouraged to assist in the investigation, as they may receive rewards of up to 30% of any successful recovery by providing original information to the SEC, highlighting the potential for increased legal scrutiny and compliance risks for the company.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, particularly concerning the authenticity of its reported 20% revenue growth in 2025.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced distributors to stockpile ASCENIV to inflate revenue figures, suggesting that without this scheme, the company would have faced a 3% revenue decline instead of the reported 20% growth.
- Stock Price Impact: This news caused ADMA Biologics' stock price to plummet by 29% over two trading days, dropping from $13.59 per share on March 23 to $9.63 per share on March 25, indicating significant market concerns regarding the company's financial health.
- Legal Options: Investors are encouraged to contact BFA for legal support, with the firm offering representation on a contingency fee basis, highlighting its commitment to protecting investor rights.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, encouraging investors to seek further information regarding their legal options.
- Revenue Growth Scrutiny: ADMA reported a 20% revenue growth in 2025, but allegations suggest this was achieved through a channel stuffing scheme to obscure declining demand, with actual revenues potentially declining by 3% had the scheme not been employed.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed ADMA's channel stuffing practices, the company's stock price fell by 29% over two trading days, from $13.59 on March 23 to $9.63 on March 25, indicating significant market concerns over its financial transparency.
- Legal Implications: Investors may have legal recourse, with BFA offering representation on a contingency basis, highlighting a commitment to protecting investor rights while potentially impacting ADMA's future financing capabilities.
See More
Investigation into ADMA Biologics for Securities Violations
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, particularly questioning the authenticity of its reported 20% revenue growth in 2025, suggesting possible channel stuffing to mask declining demand.
- Revenue Growth Concerns: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which artificially inflated revenue; without this scheme, the company would have faced a 3% revenue decline in 2025 instead of the reported growth.
- Stock Price Plunge: The news of the investigation caused ADMA Biologics' stock price to drop by 29% over two trading days, falling from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating severe market concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to submit their information for legal support, with BFA offering representation on a contingency fee basis, highlighting a commitment to protecting investor rights, which may also impact ADMA's future financing capabilities and market trust.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Announcement: Bleichmar Fonti & Auld LLP has launched an investigation into ADMA Biologics for potential violations of federal securities laws, particularly concerning the legitimacy of its reported 20% revenue growth in 2025.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV, artificially inflating revenue; without this scheme, the company would have faced a 3% revenue decline instead of the reported 20% growth.
- Stock Price Plunge: The news of the investigation led to a 29% drop in ADMA's stock price over two trading days, falling from $13.59 per share on March 23 to $9.63 on March 25, indicating significant market concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, highlighting their commitment to protecting shareholder rights.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ADMA Biologics has engaged in securities fraud or other unlawful business practices, prompting investors to reach out for more information, indicating serious concerns regarding corporate governance.
- Short Report Allegations: On March 24, 2026, Culper Research published a short report alleging that ADMA's reported growth is fictitious, driven by channel stuffing and undisclosed related party distributors, estimating a 3% revenue decline in 2025 without channel stuffing, which significantly undermines investor confidence.
- Stock Price Plunge: Following the short report's release, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share on March 24, 2026, reflecting strong market skepticism about the company's financial transparency.
- Withdrawal of Long-term Guidance: On May 6, 2026, ADMA withdrew its long-term financial guidance due to evolving competitive dynamics in the U.S. plasma products and immunoglobulin market, leading to a further stock price drop of $1.61, or 15.97%, to close at $8.47 per share on May 7, indicating increasing market pressures on the company.
See More
